MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer (Q30988899)

19 October 2017

MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer (English)

1 reference

19 October 2017

1 reference

Aleksandra Kazi

1

1 reference

19 October 2017

Guy Godwin

series ordinal

2

1 reference

19 October 2017

John Simpson

series ordinal

3

1 reference

19 October 2017

Giuseppe Sasso

series ordinal

4

1 reference

19 October 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

19 October 2017

1 reference

19 October 2017

10

1 reference

19 October 2017

472

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-10-472

19 October 2017

0 references

cites work

Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941503

The radiobiology of prostate cancer including new aspects of fractionated radiotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941503

Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941503

Australian and New Zealand three-dimensional conformal radiation therapy consensus guidelines for prostate cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941503

Prostate biopsy strategies: past, present, and future

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941503

Is alpha/beta for prostate tumors really low?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941503

Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941503

Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941503

Dose fractionation, dose rate and iso-effect relationships for normal tissue responses.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941503

Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-472

Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-472

Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-472

Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-472

Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-472

Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-472

Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-472

IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-472

Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-472

Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-472

Proton two-dimensional chemical shift imaging for evaluation of prostate cancer: external surface coil vs. endorectal surface coil

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-472

Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-472

Evaluating localized prostate cancer and identifying candidates for focal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-472

How low is the alpha/beta ratio for prostate cancer?

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20809986

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Hypofractionation for prostate cancer radiotherapy—what are the issues?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20809986

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-10-472

1 reference

Dimensions Publication ID

19 October 2017

0 references

1 reference

19 October 2017

1 reference